PBSVPBSVOTC

Overview Intelligence Charts News Fundamentals

Latest News

accessnewswire.com

Pharma-Bio Serv Announces Full Year Results and Special Dividend

DORADO, PR / ACCESS Newswire / January 29, 2026 / Pharma-Bio Serv, Inc. ("Pharma-Bio Serv" or the "Company") (OTCQB:PBSV), a regulatory affairs, quality, compliance, project management and technology transfer support consulting firm that provides services to the pharmaceutical, biotechnology, medical device, cosmetic, food and allied products industries, today announced that revenues for the year ended October 31, 2025 were approximately $9.0 million, a decrease of approximately $0.5 million when compared to last year. Additionally, a net loss for the year ended October 31, 2025 was reported of approximately $0.1 million, an improvement of approximately $0.7 million when compared to last year.

defenseworld.net

Analyzing Pharma-Bio Serv (OTCMKTS:PBSV) and ATIF (NASDAQ:ZBAI)

ATIF (NASDAQ: ZBAI - Get Free Report) and Pharma-Bio Serv (OTCMKTS:PBSV - Get Free Report) are both small-cap business services companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, earnings, institutional ownership, dividends, profitability, risk and valuation. Risk and Volatility ATIF has a beta

defenseworld.net

ATIF (NASDAQ:ZBAI) and Pharma-Bio Serv (OTCMKTS:PBSV) Financial Analysis

Pharma-Bio Serv (OTCMKTS:PBSV - Get Free Report) and ATIF (NASDAQ: ZBAI - Get Free Report) are both small-cap business services companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, risk, earnings, institutional ownership, dividends, valuation and profitability. Earnings and Valuation This table compares Pharma-Bio

accessnewswire.com

Pharma-Bio Serv Announces Results for the Quarter Ended July 31, 2025

DORADO, PUERTO RICO / ACCESS Newswire / September 15, 2025 / Pharma-Bio Serv, Inc. ("Pharma-Bio Serv" or the "Company") (OTCQB:PBSV), a compliance, project management and technology transfer support consulting firm that provides services to the pharmaceutical, biotechnology, chemical, medical device, cosmetic, food and allied products industries, today announced that revenues for the three and nine months ended July 31, 2025 were approximately $2.0 million and $6.9, million, respectively. Revenues for the three and nine months ended July 31, 2024 were approximately $2.4 million and $7.2 million, respectively.

accessnewswire.com

Pharma-Bio Serv Announces Results for the Quarter Ended April 30, 2025

DORADO, PR / ACCESS Newswire / June 16, 2025 / Pharma-Bio Serv, Inc. ("Pharma-Bio Serv" or the "Company") (OTCQB:PBSV), a compliance, project management and technology transfer support consulting firm that provides services to the pharmaceutical, biotechnology, chemical, medical device, cosmetic, food and allied products industries, today announced that revenues for the three and six months ended April 30, 2025 were approximately $2.4 million and $4.9, million, respectively. Revenues for the three and six months ended April 30, 2024 were approximately $2.3 million and $4.8 million, respectively.

accessnewswire.com

Pharma-Bio Serv Announces Results for the Quarter Ended January 31, 2025

DORADO, PUERTO RICO / ACCESS Newswire / March 17, 2025 / Pharma-Bio Serv, Inc. ("Pharma-Bio Serv" or the "Company") (OTCQB:PBSV), a compliance, project management and technology transfer support consulting firm that provides services to the pharmaceutical, biotechnology, chemical, medical device, cosmetic, food and allied products industries, today announced that revenues for the quarter ended January 31, 2025 were approximately $2.5 million, an increase of approximately $0.1 million when compared to the same period last year. Net income for the quarter ended January 31, 2025 was almost breakeven, representing an earnings increase of approximately $0.3 million when compared to the same period last year.

accessnewswire.com

Pharma-Bio Serv Announces Full Year Results

DORADO, PUERTO RICO / ACCESS Newswire / January 29, 2025 / Pharma-Bio Serv, Inc. ("Pharma-Bio Serv" or the "Company") (OTCQB:PBSV), a regulatory affairs, quality, compliance, project management and technology transfer support consulting firm that provides services to the pharmaceutical, biotechnology, medical device, cosmetic, food and allied products industries, today announced that revenues for the year ended October 31, 2024 were approximately $9.5 million, a decrease of approximately $7.5 million when compared to last year. Additionally, a net loss for the year ended October 31, 2024 was reported of approximately $0.8 million, compared to a net income of approximately $1.3 million for last year.

accessnewswire.com

Pharma-Bio Serv Announces Special Dividend

DORADO, PUERTO RICO / ACCESS Newswire / January 29, 2025 / Pharma-Bio Serv, Inc. ("Pharma-Bio Serv" or the "Company") (OTCQB:PBSV), a regulatory affairs, quality, compliance, project management and technology transfer support consulting firm that provides services to the pharmaceutical, biotechnology, medical device, cosmetic, food and allied products industries, today announced that the Board of Directors approved a Special Dividend of $0.075 per share for shareholders. The Special Dividend will be payable on or about March 20, 2025 to shareholders of record at the close of business on February 28, 2025.

accesswire.com

Pharma-Bio Serv Announces Results for the Quarter Ended July 31, 2024

DORADO, PUERTO RICO / ACCESSWIRE / September 16, 2024 / Pharma-Bio Serv, Inc. ("Pharma-Bio Serv" or the "Company") (OTCQB:PBSV), a compliance, project management and technology transfer support consulting firm that provides services to the pharmaceutical, biotechnology, chemical, medical device, cosmetic, food and allied products industries, today announced that revenues for the three and nine months ended July 31, 2024 were approximately $2.4 million and $7.2 million, respectively, a decrease of approximately $2.2 million and $6.2 million, respectively, when compared to the same periods last year. Net loss for the three and nine months ended July 31, 2024 were approximately $0.3 million and $0.8 million, respectively, compared to the same periods last year to a net income of approximately $0.5 million and $1.4 million, respectively.

accesswire.com

Pharma-Bio Serv Announces Results for the Quarter Ended April 30, 2024

DORADO, PUERTO RICO / ACCESSWIRE / June 14, 2024 / Pharma-Bio Serv, Inc. ("Pharma-Bio Serv" or the "Company") (OTCQB:PBSV), a compliance, project management and technology transfer support consulting firm that provides services to the pharmaceutical, biotechnology, chemical, medical device, cosmetic, food and allied products industries, today announced that revenues for the three and six months ended April 30, 2024 were approximately $2.4 and $4.8, million, respectively, a decrease of approximately $2.2 and $4.0 million when compared to the same periods last year. Net loss for the three and six months ended April 30, 2024 were approximately $0.2 and $0.5 million, respectively, compared to the same periods last year to a net income of approximately $0.4 and $0.8 million, respectively.

accesswire.com

Pharma-Bio Serv Announces Results for the Quarter Ended January 31, 2024

DORADO, PUERTO RICO / ACCESSWIRE / March 18, 2024 / Pharma-Bio Serv, Inc. ("Pharma-Bio Serv" or the "Company") (OTCQB:PBSV), a compliance, project management and technology transfer support consulting firm that provides services to the pharmaceutical, biotechnology, chemical, medical device, cosmetic, food and allied products industries, today announced that revenues for the quarter ended January 31, 2024 were approximately $2.4 million, a decrease of approximately $1.9 million when compared to the same period last year. Net loss for the quarter ended January 31, 2024 was approximately $270,700 compared to a net income of approximately $426,400 for the same period last year.

accesswire.com

Pharma-Bio Serv Announces Full Year Results

DORADO, PUERTO RICO / ACCESSWIRE / January 29, 2024 / Pharma-Bio Serv, Inc. ("Pharma-Bio Serv" or the "Company") (OTCQB:PBSV), a regulatory affairs, quality, compliance, project management and technology transfer support consulting firm that provides services to the pharmaceutical, biotechnology, medical device, cosmetic, food and allied products industries, today announced that revenues for the year ended October 31, 2023 were approximately $17.0 million, a decrease of approximately $2.4 million when compared to last year. Additionally, net income for the year ended October 31, 2023 was approximately $1.3 million, an improvement of approximately $0.3 million when compared to last year.

accesswire.com

Pharma-Bio Serv Announces Special Dividend

DORADO, PUERTO RICO / ACCESSWIRE / December 21, 2023 / Pharma-Bio Serv, Inc. ("Pharma-Bio Serv" or the "Company") (OTCQB:PBSV), a compliance, project management and technology transfer support consulting firm that provides services to the pharmaceutical, biotechnology, chemical, medical device, cosmetic, food and allied products industries, today announced that the Board of Directors approved a Special Dividend of $0.075 per share for Shareholders. The Special Dividend will be payable on or about February 15, 2024 to shareholders of record at the close of business on January 30, 2024.

accesswire.com

Pharma-Bio Serv Announces Results for the Three and Nine Months Ended July 31, 2023

DORADO, PUERTO RICO / ACCESSWIRE / September 14, 2023 / Pharma-Bio Serv, Inc. ("Pharma-Bio Serv" or the "Company") (OTCQB:PBSV), a compliance, project management and technology transfer support consulting firm that provides services to the pharmaceutical, biotechnology, chemical, medical device, cosmetic, food and allied products industries, today announced that net income for the three and nine months ended July 31, 2023 was approximately $0.5 and $1.4 million, respectively, an increase of approximately $0.2 and $0.5 million, when compared to the same periods last year. Revenues for the three and nine months ended July 31, 2023 were approximately $4.6 and $13.4 million, respectively, a decrease of approximately $0.2 and $1.4 million, respectively, when compared to the same periods last year.

investorplace.com

7 Best Penny Stocks Under $1 to Buy in July

While the market offers myriad avenues for high-risk speculation, the best penny stocks under $1 may present some of the most sweat-inducing, blood-pressure-racing moments ever. Yeah, sure, they're priced below a buck – what can go wrong?

investorplace.com

7 Best Penny Stocks Under $1 to Buy Now

Anyone looking for the best penny stocks under $1 to buy likely knows how much risk this kind of speculation entails. However, it bears repeating: The ideas presented below carry incredible risk and volatility.

accesswire.com

Pharma-Bio Serv Announces Results for the Quarter Ended July 31, 2021

DORADO, PUERTO RICO / ACCESSWIRE / September 14, 2021 / Pharma-Bio Serv, Inc. ("Pharma-Bio Serv" or the "Company") (OTCQB:PBSV), a regulatory, compliance, project management and technology transfer support consulting firm that provides services to the pharmaceutical, biotechnology, medical device, cosmetic, food and allied products industries, today announced revenues for the three and nine months ended July 31, 2021 were approximately $4,988,000 and $14,518,000, respectively, a decrease of approximately $1,290,000 and $2,021,000, respectively, when compared to the same periods last year. Net income for the three and nine months ended July 31, 2021 was approximately $2,275,000 and $2,783,000, an increase of approximately $1,583,000 and $876,000 when compared to the same periods last year, respectively.

accesswire.com

Pharma-Bio Serv Announces Results for the Quarter Ended April 30, 2021

Announces Regulatory and Compliance Advisory Board DORADO, PUERTO RICO / ACCESSWIRE / June 14, 2021 / Pharma-Bio Serv, Inc. ("Pharma-Bio Serv" or the "Company") (OTCQB:PBSV), a compliance, project management and technology transfer support consulting firm that provides services to the pharmaceutical, biotechnology, chemical, medical device, cosmetic, food and allied products industries, today announced revenues for the three and six months ended April 30, 2021 were $5,042,000 and $9,530,000, respectively, a decrease of approximately $606,000 and $731,000, respectively, when compared to the same periods last year. Net income for the three and six months ended April 30, 2021 was approximately $240,000 and $508,000, a decrease of approximately $448,000 and $706,000 when compared to the same periods last year, respectively.

accesswire.com

Pharma-Bio Serv Announces Results for the Quarter Ended January 31, 2021

DORADO, PUERTO RICO / ACCESSWIRE / March 17, 2021 / Pharma-Bio Serv, Inc. ("Pharma-Bio Serv" or the "Company") (OTCQB:PBSV), a compliance, project management and technology transfer support consulting firm that provides services to the pharmaceutical, biotechnology, chemical, medical device, cosmetic, food and allied products industries, today announced that revenues for the quarter ended January 31, 2021 were approximately $4,488,000, a decrease of approximately $125,000 when compared to the same period last year. Additionally, net income for the quarter ended January 31, 2021 was approximately $268,000, a decrease of approximately $259,000 when compared to the same period last year.

Loading news...

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance